The standard of care for non-metastatic renal cancer is surgical resection followed by adjuvant therapy for those at high risk for recurrences. However, for older patients, surgery may not be an option due to the high risk of complications which may result in death. In the past renal cancer was considered to be radio-resistant, and required a higher dose of radiation leading to excessive complications secondary to damage of the normal organs surrounding the cancer. Advances in radiotherapy technique such as stereotactic body radiotherapy (SBRT) has led to the delivery of a tumoricidal dose of radiation with minimal damage to the normal tissue. Excellent local control and survival have been reported for selective patients with small tumors following SBRT. However, for patients with poor prognostic factors such as large tumor size and aggressive histology, there was a higher rate of loco-regional recurrences and distant metastases. Those tumors frequently carry program death ligand 1 (PD-L1) which makes them an ideal target for immunotherapy with check point inhibitors (CPI). Given the synergy between radiotherapy and immunotherapy, we propose an algorithm combining CPI and SBRT for older patients with non-metastatic renal cancer who are not candidates for surgical resection or decline nephrectomy.
Frontiers in oncology. 2024 May 24*** epublish ***
Nam P Nguyen, Monica-Emilia Chirila, Brandi R Page, Vincent Vinh-Hung, Olena Gorobets, Mohammad Mohammadianpanah, Huan Giap, Meritxell Arenas, Marta Bonet, Pedro Carlos Lara, Lyndon Kim, Fabien Dutheil, David Lehrman, Luis Zegarra Montes, Ghassen Tlili, Zineb Dahbi, Gokoulakrichenane Loganadane, Sergio Calleja Blanco, Satya Bose, Elena Natoli, Eric Li, Abba Mallum, Alessio G Morganti
Department of Radiation Oncology, Howard University, Washington, DC, United States., Department of Clinical Development, MVision AI, Helsinki, Finland., Department of Radiation Oncology, Johns Hopkins University, Baltimore, MD, United States., Department of Radiation Oncology, Centre Hospitalier Public du Contentin, Cherbourg-en-Contentin, France., Department of Oral Surgery, University Hospital of Martinique, Fort-de-France, France., Colorectal Research Center, Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran., Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC, United States., Department of Radiation Oncology, Sant Joan de Reus University Hospital, University of Rovira, I Virgili, Tarragona, Spain., Department of Radiation Oncology, Arnau de Vilanova University Hospital, Lleida, Spain., Department of Radiation Oncology, Fernando Pessoria Canarias Las Palmas University, Las Palmas, Spain., Division of Neuro-Oncology, Mount Sinai Hospital, New York, NY, United States., Department of Radiation Oncology, Clinique Sainte Clotilde, Saint-Denis, Reunion Island, France., Department of Radiation Oncology, International Geriatric Radiotherapy Group, Washington, DC, United States., Department of Urology, University of Peruana, Lima, Peru., Department of Urology, Sahloul University Hospital, Sousse, Tunisia., Department of Radiation Oncology, Mohammed VI University of Health Sciences, Casablanca, Morocco., Department of Radiation Oncology, Institut Curie, Paris, France., Department of Oral Maxillofacial Surgery, Howard University, Washington, DC, United States., Department of Radiation Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Azienda Ospedaliera-Universitaria di Bologna, Bologna, Italy., Department of Pathology, Howard University, Washington, DC, United States., Department of Radiation Oncology, University of KwaZulu Natal, Durban, South Africa.